Keith Meister Biography and Net Worth

Director of Illumina

Keith Meister was appointed as a director in March 2025. Mr. Meister is the Managing Partner and Chief Investment Officer of Corvex Management LP, which he founded in December 2010.

Prior to founding Corvex, Mr. Meister served as Chief Executive Officer and then Principal Executive Officer and Vice Chairman of the Board of Icahn Enterprises from August 2003 to August 2010.

In addition to Illumina, Mr. Meister currently serves on the Board of Directors for GeneDx, MGM Resorts and Vestis. He has previously served as a director on numerous other public boards including Yum! Brands, Inc., The Williams Companies, The ADT Corporation, Ralcorp Holdings, and Motorola/Motorola Mobility, among others. He is also Chairman of the Board of Directors for Harlem Children’s Zone and a member of the Board of Trustees for the American Museum of Natural History.

Keith received an A.B. in government, cum laude, from Harvard College in 1995.

What is Keith A. Meister's net worth?: The estimated net worth of Keith A. Meister is at least $758.58 million as of May 13th, 2026. Mr. Meister owns 4,598,297 shares of Illumina stock worth more than $758,581,056 as of May 29th. This net worth estimate does not reflect any other investments that Mr. Meister may own. Learn More about Keith A. Meister's net worth.
How do I contact Keith A. Meister?: The corporate mailing address for Mr. Meister and other Illumina executives is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. Illumina can also be reached via phone at (858) 202-4500 and via email at [email protected]. Learn More on Keith A. Meister's contact information.
Has Keith A. Meister been buying or selling shares of Illumina?: During the last quarter, Keith A. Meister has sold $47,930,980.47 in shares of Illumina stock. Most recently, Keith A. Meister sold 104,393 shares of the business's stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $145.34, for a transaction totalling $15,172,478.62. Following the completion of the sale, the director now directly owns 3,500,048 shares of the company's stock, valued at $508,696,976.32. Learn More on Keith A. Meister's trading history.
Who are Illumina's active insiders?: Illumina's insider roster includes Alexander Aravanis (SVP), Frances Arnold (Director), Charles Dadswell (SVP), Scott Davies (Chief Legal Officer), Francis deSouza (CEO), Phillip Febbo (SVP), Jay Flatley (Director), Scott Gottlieb (Director), Aimee Hoyt (SVP), Patricia Leckman (SVP), Karen Mcginnis (CAO), Keith Meister (Director), Robert Ragusa (SVP), Mostafa Ronaghi (SVP), Sam Samad (CFO), Jacob Thaysen (CEO), Susan Tousi (SVP), Mark Van Oene (SVP), and Christensen Wedel (SVP). Learn More on Illumina's active insiders.
Are insiders buying or selling shares of Illumina?: In the last year, Illumina insiders bought shares 2 times. They purchased a total of 700 shares worth more than $84,627.00. In the last year, insiders at the life sciences company sold shares 5 times. They sold a total of 332,853 shares worth more than $48,347,612.14. The most recent insider tranaction occured on May, 14th when Director Keith A Meister sold 104,393 shares worth more than $15,172,478.62. Insiders at Illumina own 2.9% of the company. Learn More about insider trades at Illumina.
Information on this page was last updated on 5/14/2026.

Keith A. Meister Insider Trading History at Illumina

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/14/2026	Sell	104,393	$145.34	$15,172,478.62	3,500,048
5/13/2026	Sell	225,067	$145.55	$32,758,501.85	3,604,441

Keith A. Meister Buying and Selling Activity at Illumina

Illumina Company Overview

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Today's Range

Now: $165.12

$158.10

$165.37

50 Day Range

MA: $132.92

$117.67

$158.70

2 Week Range

Now: $165.12

$78.79

$165.37

Volume

869,268 shs

Average Volume

1,850,214 shs

Market Capitalization

$24.98 billion

P/E Ratio

30.05

Dividend Yield

N/A

Beta

1.42